Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00907283
Other study ID # Deferiprone08
Secondary ID EUDRACT NUMBER 2
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date November 2008
Est. completion date December 2024

Study information

Verified date February 2023
Source Ente Ospedaliero Ospedali Galliera
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial is a multicenter, unblinded, single-arm pilot study, lasting one year (plus one year extension Amendment n.3 25 August 2009, plus two years follow-up Amendment n.7) , to evaluate the efficacy and safety of the chelator therapy with deferiprone on cerebral iron accumulations. The drug will be administered in the dosage of 15 mg/kg twice daily. The safety and tolerability of the drug will be evaluated by measuring hemochrome every seven days with leukocyte formula count. At 3, 6 and 12 months from the start of treatment, a neurological evaluation will be performed using several specific evaluation scales (International Cooperative Ataxia Rating Scale (ICARS); Unified Parkinson's Disease Rating Scale (UPDRS); Burke-Fahn-Marsden (BFM)). Every 6 months of treatment, a brain magnetic resonance image (MRI) aimed at measuring iron overload quantitatively, if possible.


Description:

The time interval between Study Start Date and Study First Received was related to bureaucratic problems. The treatment of systemic iron overload has in recent years improved notably since new drugs and new therapeutic combinations have become available for use. Conversely, therapies for the removal of regional iron overloads on the cerebral level have not been described in the literature. As it is known, the symptoms resulting from a cerebral iron overload are strongly disabling, reducing the patient's autonomy. Considering that valid therapeutic alternatives of proven preventive and/or curative efficacy in these neurodegenerative diseases do not exist today, the use of lipophilic iron chelators must be considered as a possible therapeutic strategy worthy of deeper study. Deferiprone is an oral active iron chelator, the use of which is authorized for the treatment of iron overload in patients affected by thalassemia major in conditions of "chelation not suitable for Desferal." In recent years, deferiprone has been applied extensively, demonstrating a good efficacy and tolerability profile. Unlike deferoxamine, a hydrophilic drug, deferiprone presents chemical-physical characteristics (low molecular weight, favourable octanol:water partition coefficient, neutral charge) that guarantee drug good permeability of mitochondrial walls and the blood-brain barrier. In a recent study deferiprone (commercial name Ferriprox) was used in 13 patients with Friedreich's ataxia (FA), also treated with idebenone (an experimental drug with an anti-oxidant action), compared with 9 patients affected by FA but treated only with Idebenone. The 9 patients who completed the 6 months of treatment with deferiprone were evaluated from a clinical point of view using the ICARS Scale (International Cooperative Ataxia Rating Score) before the start and after 1 and 6 months of therapy. They also performed a cerebral Magnetic Resonance Imaging before and after 1, 2, 4 and 6 months of treatment. The results were promising. In fact, after 6 months of therapy, a reduction in iron accumulation in specific cerebral areas involved in the pathogenesis of neurodegenerative disease was demonstrated. The patients also presented a significant clinical improvement confirmed by the ICARS score. Therefore the use of deferiprone, despite the possible side effects (such as gastrointestinal disturbances, a temporary increase in transaminases, and especially agranulocytosis found in about 1% of patients treated with deferiprone), currently represents the only possibility for removing and/or preventing the accumulation of iron in the central nervous system, curing and/or avoiding the most severe and debilitating consequences of a disease for which another therapy does not exist. The Centers that specialize in the treatment of iron accumulation have acquired significant experience in the use of new oral iron chelators over the last 10 years, which permits deferiprone to be used carefully and safely in the three cases at hand. We therefore propose the use of this drug for treating patients who show neurological symptoms that can be correlated with a cerebral iron overload shown through MRI and who have not benefited from other therapies.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 1 Year to 80 Years
Eligibility Inclusion Criteria: - Patients over > 1 years of age who have neurological symptoms that can be correlated with cerebral-level iron overload as documented with MRI.This inclusion criteria has been amended by Amendment 6, 24 march 2011) - Patients who have given informed consent. Exclusion criteria: - Inability to be subjected to MRI exam. - Renal insufficiency (creatinine > 1.5 mg/dl). - Neoplasias. - Patients with average levels of ALT > 300 and patients with variations of ALT or AST of 300% during the year prior to enrolling. (At least 4 measurements in 12 months). - Systemic cardiovascular, renal, hepatic etc., diseases that could counter-indicate the therapeutic options specified. - Known hypersensitivity to deferiprone. - Patient judged potentially unreliable and/or uncooperative with regard to study procedures. - Pregnancy and breastfeeding.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Deferiprone
15 mg/Kg/twice for 1 year

Locations

Country Name City State
Italy Neurological Pathology Department, Brotzu Hospital Cagliari
Italy Centre of Microcitemia and Congenital Anemias, Galliera Hospital Genoa
Italy Clinic of Neurology, University of Genoa Genoa

Sponsors (1)

Lead Sponsor Collaborator
Ente Ospedaliero Ospedali Galliera

Country where clinical trial is conducted

Italy, 

References & Publications (2)

Abbruzzese G, Cossu G, Balocco M, Marchese R, Murgia D, Melis M, Galanello R, Barella S, Matta G, Ruffinengo U, Bonuccelli U, Forni GL. A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica. 2011 Nov;96(11):1708-11 — View Citation

Forni GL, Balocco M, Cremonesi L, Abbruzzese G, Parodi RC, Marchese R. Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov Disord. 2008 Apr 30;23(6):904-7. doi: 10.1002/mds.22002. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the efficacy and safety of the chelator therapy with deferiprone on cerebral iron accumulations. Safety:CBC including ANC will be monitored weekly.If the liver enzymes are greater than 2.5 fold the upper limit of normal, the drug will be withheld and the assessment repeated in 1 week. If the laboratory values continue to be over 2.5 times the upper limit of normal or if the neutrophil counts decrease to less than 1.5 x 109/L (1500 cells/µl) the Patient will be withdrawn from the study. Neutropenia/Agranulocytosis is confirmed as an Absolute Neutrophil Count being less than 1.5 x 109/L (1500 cells/µl) if counts on two consecutive days are both less than 1.5 x 109 (1500 cells/µl). 6 months + 6 months (plus one year extension)
See also
  Status Clinical Trial Phase
Recruiting NCT04423237 - Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT
Completed NCT04614779 - Long-term Clinical Study of CN128 in Thalassemia Patients Phase 2
Withdrawn NCT03800446 - Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood N/A
Not yet recruiting NCT02833493 - Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload N/A
Completed NCT02164253 - Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients Phase 2
Completed NCT00901199 - Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload Phase 2
Completed NCT00512226 - Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia N/A
Recruiting NCT00378469 - Study of the Effects of Muscular Activity on Iron Metabolism N/A
Completed NCT00117507 - Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients Phase 4
Completed NCT00138684 - Cytochrome P450 2E1 and Iron Overload Phase 2
Completed NCT03990181 - Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplement N/A
Terminated NCT02274233 - Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia Phase 1
Active, not recruiting NCT01443195 - Iron Metabolism in Small Pre Term Newborns N/A
Completed NCT01546415 - Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia Phase 4
Completed NCT01572818 - Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients N/A
Not yet recruiting NCT00980421 - Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children Phase 3
Completed NCT01047098 - Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation N/A
Recruiting NCT05294471 - Fully Automated High-Throughput Quantitative MRI of the Liver
Completed NCT03591575 - Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children Phase 4
Completed NCT01376622 - Changes in Pituitary Iron and Volume With Deferasirox